Industrially-optimised expression platforms routinely achieve mAb titres of up to 10 g/L in fed batch cultures with dramatically reduced development timelines. Improvements in productivity and quality of host cells lines have been made through "brute force" modification and screening of media and feeds , and selection of host cell line. However, efforts remain to transition CHO expression systems from reliable workhorses to state-of-the-art protein producing powerhouses. CHO-derived mAbs have historically offered a low risk development pathway that relies on platform expression, development, manufacturing technology and infrastructure. The evolving biopharmaceutical landscape demands more flexibility. Diversification of product types, from traditional mAbs to novel modalities, presents various challenges. Moreover, the imperative to reduce time, cost and environmental impact necessitates innovative new approaches. Despite significant advancements in CHO expression systems, a fundamental understanding of the underlying cellular mechanisms driving improved bioprocess performance remains elusive. This knowledge gap often necessitates time consuming and resource intensive empirical optimization. The development of predictive biomarkers could significantly enhance biopharmaceutical development by enabling early-stage selection of high performing cell lines and processes, thereby reducing the reliance on extensive empirical screening. 'Omics' technologies such as metabolomics and proteomics are often used in healthcare research, providing mechanistic insights into disease states and in turn identifying biomarkers and drug targets. Whilst these technologies offer invaluable information, their widespread adoption in industrial biotechnology is hindered by the need for specialised instrumentation, complex sample preparation and lengthy analysis.